Title: "Novel Clinical Manifestations of Human Monkeypox Virus Infection and Current Therapeutic and Preventive Strategies: A Systematic Review."

Name of the Authors: ¹Santenna Chenchula,²Mohan Krishna Ghanta, ³Madhavrao Chavan, ⁴Krishna Chaitanya Amerneni, '6Padmavathi R, ⁵Rupesh Gupta

Running Title: Review of Monkeypox outbreak 2022 & Potential therapeutics.

The affiliation(s) of the author(s):

- 1. *Santenna Chenchula, Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, India. Email: csanten7@gmail.com.
- 2. Mohan Krishna Ghanta, Assistant Professor, Department of Pharmacology, MVJ Medical College and Research Hospital, Bangalore, Karnataka, Email: mohanakrishna.ghanta@gmail.com
- 3. Madhavrao Chavan, Associate Professor, Department of Pharmacology, All India Institute of Medical Sciences, Mangalagiri, India. Email: madhavrao.pharm@aiimsmangalagiri.edu.in
- 4. Krishna Chaitanya Amerneni, Faculty, Western Michigan University, Kalamazoo, Michigan. Email: krishnachaitanya.amerneni@med.wmich.edu
- 5. Padmavathi R, Resident, SVSMCH, Mahbubnagar, Telangana, India, Email: pad.mythili@gmail.com.
- 6. Rupesh Gupta, Assistant Professor, Department of Internal Medicine, Government Medical College, Shahdol, Madhya Pradesh, India. Email: neolog.raj@gmail.com.

*Corresponding Author: Santenna Chenchula, Department of Pharmacology, All India Institute of Medical Sciences, Bhopal, India, 462020, Madhya Pradesh, India.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Phone no: 7987220348

Email Id: csanten7@gmail.com.

Total number of pages: 14

The total number of Tables/Graphs: 1

Total number of Images: 1

Word counts

For abstract: 204.

For the text: 3259 (excluding references)

Prior publication: Nil

Sources of Support: Nil

Conflicts of interest: Nil

Read and approved by all authors: Yes

Abstract:

2

The escalating global monkeypox cases since early May 2022, acquired by the monkeypox virus (MPXV), a double-stranded DNA virus has been declared a public health emergency of international concern by the World Health Organization (WHO). Globally as of December 2022, the

MPXV was transmitted to more than 100 countries with around 82,550 cases, among which 81577 cases from the 103 countries that are non-

endemic to the MPXV with more than 50 deaths. The ripple effect of the Monkeypox outbreak in nonendemic countries globally could

potentially bring significant challenges to worldwide health systems if the spread of the virus is not effectively controlled. In this urgent situation,

only three antiviral drugs are in use against monkeypox infections and are not specific against monkeypox, hence the scientific communities

across the world are in search to explore vaccines or therapeutic antiviral drugs selectively against the monkeypox virus. Here, in the present

review, we discuss the clinical characteristics and treatment outcomes of the ongoing MPX outbreak of 2022 in nonendemic countries globally,

from the published and grey literature in PubMed, Scopus and Google scholar. A total of 17 studies with 17,811 of MPX cases were found and

included in the final qualitative analysis of the current systematic review.

Keywords: Monkeypox; Novel Antivirals; Monkeypox outbreak 2022; Tecovirimat;

Main File

Background:

3

In the present smallpox post-eradication era, monkeypox (MPX) has emerged as the most important and high-threat orthopox virus infection

spread among humans [1]. Monkeypox virus (MPXV), is the causative agent of the MPX infection, a double-stranded DNA virus with an

envelope belonging to the orthopoxvirus genus of the family Poxviridae. Recently, the WHO renamed monkeypox as "mpox". Since early May

2022, a rapid surge in the cases of monkeypox from more than 100 non-endemic countries and some endemic counties across the world is a

worrisome and highly considerable public health issue [1]. Globally as of December 2022, the MPX virus transmitted to more than 100 countries with around 82550 cases, among which 81577 cases were from the 103 countries that are non-endemic to the MPX virus with more than 50 deaths from non-endemic countries have been reported current MPX outbreak [1-2]. The two common MPV transmissions are animal-to-human and human-to-human [3]. The WHO reported that in the past 30 years, monkeypox was endemic in several African countries with most suspected cases of MPX occurring in the Democratic Republic of the Congo till May 2022[1]. There are two distinct clades of monkeypox virus, the Congo Basin clade (endemic in Central Africa) and the West African clade [1-2]. On July 23, the WHO Director-General declared the escalating global monkeypox outbreak a Public Health Emergency of International Concern (PHEIC), highlighting the need for an effective and equitable response that includes accelerated access to diagnostic testing, vaccination and treatment. Because of the several animal reservoirs, complete eradication of MPXV is not possible [1].

To curtail the rapid spread and severity of MPXV epidemics in nonendemic regions of the world, it is necessary to have an in-depth understanding of the virology, transmission, clinical symptoms and management strategies of the current monkeypox outbreak 2022 reported cases of MPX infection. There is a dearth of information on the novelty of the current MPX outbreak clinical virology, transmission, signs and symptoms as well as treatment outcomes of MPX infection in non-endemic regions. Therefore, in the present review, we have analysed to identify the novel clinical characteristics of the current MPX outbreak reports across the world from the published and grey literature.

Methodology:

We conducted a systematic literature search from the 1st May 2022 to December 2022 in the PubMed, Cochrane Library, Google Scholar databases and grey literature using the Mesh terms or keywords "Human Monkeypox" OR "Monkeypox" OR "Monkeypox Virus" OR "MPX" OR "MPXV", to study the current MPX outbreak clinical characteristics and treatment outcomes in the non-endemic regions across the world. A comprehensive review of the published and grey literature on the current outbreak, to inform the novel clinical characteristics of the current Monkeypox outbreak and treatment outcomes in comparison to previously reported MPX infection clinical characteristics in the nonendemic countries across the world.

Results:

5

In the present review, we discuss the clinical characteristics and treatment outcomes of the ongoing MPX outbreak of 2022 in nonendemic countries globally, from the published and grey literature in PubMed, Scopus and Google scholar. A total of 17 studies with 17,811 of human MPX cases were found and included in the qualitative analysis [Figure 1].

Epidemiology, Clinical Characteristics, Transmissibility and Diagnosis of Human MPX infection in the previous Outbreaks:

The monkeypox virus first replicates at the site of inoculation, spreads to nearby lymph nodes, and causes viremia during the incubation period, which lasts for roughly 7 to 14 days. Thereafter, a prodromic stage is characterized by fever, chills, headache, sweats, fatigue, sore throat, muscle ache, and lymphadenopathy [4-5]. However, all patients may not report initial prodromal illness and it may start as a rash with lesions progressing through several stages [4-5]. Commonly, the prodromal stage may last for five days, followed by a skin eruption phase which usually manifests within one to four days of the appearance of fever and lymphadenopathy and is characterized by a few to several thousand lesions as 2 to 5 mm diameter macules and continues for a period of two to three weeks [4-5]. Secondary bacterial infection and dehydration are more common due to the disruption of skin from the lesions [4]. Lymphadenopathy occurring in the early stage of the illness is a typical sign of monkeypox differentiating human monkeypox from smallpox and chickenpox [5]. The rash associated with monkeypox is often described as painful, but in the healing phase or crusts it can become itchy and the rash develops from macules through papules, vesicles, pustules, and ultimately crusts [6]. Gastrointestinal symptoms are also often experienced by patients with MPX including, diarrhoea, vomiting, decreased appetite and dysphagia [7]. In addition, most commonly MPX infections affect the eyes causing secondary bacterial infections leading to swollen and red eyes, sensitivity to light and in severe cases it may lead to loss of vision [8]. In some cases, the respiratory tract is also affected causing severe cough, difficulty in breathing or bronchopneumonia [8]. In severe cases, serious complications such as encephalitis and sepsis are common causes of mortality [9]. Monkeypox case fatality rates vary depending on the virus lineage and range from 1% to 11%., but among the voungest children and immunocompromised patients, it was high (15%) [1-2, 5].

The human-to-human transmission was high with the Congo Basin clade and less with the West African clade, but the outbreaks of the West African clade in Nigeria have shown a high transmission between close contacts than initially reported [1-2]. In addition to direct contact with lesion material or body fluids, person-to-person transmission can also occur through large respiratory droplets after prolonged face-to-face contact [10-11]. Virus-contaminated materials, including mattresses and clothing, can also transmit the disease [12]. There have been reports of the MPXV spreading from the affected mother to the fetus [13]. Case studies of miscarriage and fetal death with the stillborn showing diffuse cutaneous maculopapular skin lesions exist [14].

Although serological and antigen detection tests can be useful when no virologic specimen is available, still they cannot offer a conclusive diagnosis [15]. Serologic testing identifies anti-orthopoxvirus IgG and/or IgM antibodies in the absence of recent vaccination [15]. The MPXV DNA identification by Reverse transcriptase polymerase chain reaction (RTPCR) on lesion specimens is the definitive diagnostic test for MPX infection [14]. The most specific specimen used for the diagnosis of the MPX includes two samples of lesion swabs based on the disease phase [15]. Monkeypox patients frequently have abnormal aminotransferases, leukocytosis, thrombocytopenia, and hypoalbuminemia in their laboratory tests. Acute inflammation, significant spongiosis, keratinocyte ballooning degeneration, and cutaneous oedema can all be associated with various viral infections, according to histopathological examination [15].

Epidemiology, Clinical Characteristics, Transmissibility and Diagnosis of Human MPX infection in the Current Monkeypox Outbreak 2022

The published and grey literature related to the present outbreak yielded a total of 17 studies (n=17,811) from 1st May 2022 to December 2022. Predominantly, most of the studies are from the Europe continent, where the monkeypox virus was not endemic. In the present outbreak of 2022, the transmission of MPXV is between person-to-person and has intricated epidemic in several nations to date. The median age group infected in the current outbreak was 30-40 years young adults and the majority were males [16-17, 20-29, 40, 56,59,61-64]. So far, in the MPX outbreak 2022, most of the reported cases but not exclusively have been identified in men who have recent sexual contact with new or multiple male partners [1]. The primary risk factor for MPXV transmission is thought to be sexual contact [13,18-19]. In some cases of young children, household transmission has also occurred. Typical symptoms seen in the present MPX outbreak include rashes at various sites of the body anogenital lesions, mucosal lesions, fever, lethargy, myalgia, headache, lymphadenopathy (cervical, axillary, Inguinal), influenza-like illness, sore throat, nasal congestion, cough, proctitis, tonsillitis, bacterial skin abscess, vesicular-umbilical and pseudo-pustular skin lesions, asthenia, exanthema, skin lesions in the arm, perianal and trunk area, genital area, chest and legs, wrist, pectoral, fingers, hand, ulcerated ventral tongue, genital vesicles, odynophagia, perianal Abscess, tonsillar abscess, sore throat, rectal pain with rectal perforation, Penile oedema[20-29,40,56,59,61-64]. There are many atypical clinical symptoms observed in the current Monkeypox Outbreak 2022 such as, not all patients reported initial prodromal febrile illness and it started as a rash appearing as pimples or blisters and painful or itchy with lesions progressing

through several stages including scabs before healing or only flu-like symptoms or only lesions in the anogenital region and the mouth, hands, palms and alimentary tract areas, rectal pain and penile oedema without any prodromal symptoms[18-29,40,56]. In a case series of 2022 outbreaks, study findings have shown that the MPXV DNA was found in semen samples, which was unknown in previous reports that the virus can spread through vaginal or semen fluids [18, 29]. Patients are contagious as soon as their illness develops., and the infectious lesions comprise viruses throughout disease phases until all skin lesions are scraped over and reepithelialization has occurred, which can take up to 4 weeks [17]. The mean incubation period was 7 (3-21) days [20-29]. For the confirmation of monkeypox virus diagnosis, Swab specimens of the skin or genital lesions, exudate and/or crusts from lesions in the palms, throat or nasopharyngeal, semen, urine and faeces and blood by using Reverse transcriptase polymerase chain reaction (RTPCR) test [20-29, 40, 56,59,61-64]. Studies have also shown that monkeypox DNA was detected in the saliva, vaginal and seminal fluid of infected patients [20]. Surprisingly in the present outbreak, DNA of MPXV was also found in the anal or oropharyngeal swabs of asymptomatic MSM [60-61].

Patients hospitalized for the treatment of severe painful bacterial anogenital infections [20-29, 40,56,59,61-64]. The majority were suffering from human immunodeficiency virus (HIV) and other sexually transmitted diseases (STDs) [20-29, 40, 56,59,61-64]. The majority of patients were hospitalized due to concomitant severe bacterial infections and rectal pain, and proctitis and were treated for secondary bacterial infections with antimicrobials, and supportive treatment including anti-inflammatory, and antihistaminic medications. The most common antiviral agents used for the treatment of MPX infection include oral tecovirmat, brincidofovir and topical cidofovir (eye involvement). In the present outbreak,

the case fatality rate was 3-6% [1]. However, there were two deaths reported in the presentation including studies. Overall, when compared to previously documented outbreak reports in endemic west and central African regions in the past 30 years, the clinical pattern of the monkeypox cases in non-endemic regions of the present outbreak has been completely atypical, varying in MSM and the manifestations among infected. Unexpectedly, cases with no symptoms had MPXV DNA positive tests as well. In contrast to outbreaks in endemic locations, there is a higher rate of hospitalization for the management of pain and necrotizing secondary bacterial infection in the anorectal region. The majority of the reported MPXV cases were associated with sexual contact only and the viral DNA has been identified even in seminal, anogenital and saliva samples along with swabs from skin lesions. **Table 1 Presents Clinical Studies of the Monkeypox Outbreak 2022** [20-29, 40, 56,59,61-64].

Current Preventive and Treatment Strategies:

10

Based on the findings of earlier studies from countries where monkeypox is endemic, patients with MPX may benefit from medical supportive treatment to lessen the effects of lesions, which comprises preventing and treating secondary complications, maintaining sufficient hydration and nutrition, and safeguarding susceptible anatomical areas like the eyes and genitalia [30-31]. Currently, only one antiviral agent, tecovirmat is approved by the United States Food and Drug Administration (USFDA) for the treatment of human smallpox disease caused by the *Variola virus* in adults and children [32-33]. However, tecovirimat is being made available through the United States Centre for Disease Control (USCDC) under an FDA authority called Expanded Access or "compassionate use." There are currently no human data demonstrating the efficacy of tecovirimat for the treatment of monkeypox, or the safety and pharmacokinetic profile. While there are no MPXV-specific antivirals currently

approved, the US CDC and WHO Interim Clinical Guidelines recommended three antiviral agents such as tecovirimat, cidofovir and brincidofovir for the treatment of MPX infection, have been made available to treat monkeypox via an expanded access Investigational New Drug (IND) protocol [32-33]. According to the CDC and WHO interim guidelines, the aforementioned antiviral agents should be considered only in patients with monkeypox with severe disease and those at risk for severe diseases such as pregnant or breastfeeding women, patients younger than eight years of age, patients with complications of the infection and in patients with monkeypox caused by accidental implantation in the eyes, mouth, or other areas along with supportive treatment [32-33]. There are oral capsules and injectable forms of Tecovirimat that can be used intravenously [32-33]. To increase oral absorption, tecovirimat should be given along with a high-fat meal [32-33]. Currently, there are several clinical trials of tecovirmat are underway or planned (PALM-007, PLATINUM, WHO/ARNS, and ACTG5418) all over the world to provide required data on the safety and efficacy of monkeypox infection [32-33]. A recent case series of 25 patients with confirmed MPX infections who received a course of tecovirmat therapy for 14 days (one patient for 21 days) on weight-based, for every 8 or 12 hours, on compassionate use basis concluded that oral treatment with tecovirimat was well tolerated, with minimal adverse drug reactions [59].

Vaccinia Immune Globulin Intravenous (VIGIV), a hyperimmune globulin is also indicated by the US CDC guidelines, particularly in individuals with immunodeficiencies or individuals for whom vaccination is contraindicated [32-34]. If monkeypox lesions involve the eyes (conjunctivitis and oedema of the eyelids, focal lesions on the conjunctiva and along the margins of the eyelids) off-label use of trifluridine or vidarabine eye drops or ointments applied every four hours for 7 to 10 days with or without intravenous VIG are indicated [31,34-36]. However,

topical corticosteroids to control inflammation may lead to virus persistence and prolonged corneal damage, hence steroids should not be used for treating monkeypox involving the eyes [33-34]. Enhanced lubrication or topical antibiotics could be considered for monkeypox involving the eyes [31, 35]. To avoid long-term ocular problems such as chronic pain, corneal opacity, scar tissue, and permanent loss of vision, an early therapy to enhance virus elimination may be taken into consideration in MPX patients [36-55]-

Evidence from the literature has shown that the smallpox vaccine protects 85% against monkeypox via cross-immunity [36]. There are three available vaccines for orthopoxvirus: ACAM2000, MVA-BN7 or JYNNEOS (Imvamune or Imvanex) and LC16 [32, 37-38, 50]. However, no data is available yet on the effectiveness of these vaccines in the current outbreak. The first-generation vaccines are smallpox vaccines produced by propagated and harvested primarily from the skin of live animals, infecting the abdomen and flanks of calves or other large animals (e.g., calf, sheep, water buffalo lymph) or chorioallantois membrane (CAM) of embryonated hens' eggs during the intensified smallpox eradication program consist of live vaccinia virus [36, 55]. However, the same *Vaccinia virus* strains used to produce the first-generation vaccinations are used to produce the second-generation smallpox vaccines (ACAM2000) using designated cell lines, or clonal virus strains plaque-purified from conventional vaccine stocks [50,55]. Later, the third-generation vaccines were produced and specifically developed as safer vaccines towards the end of the eradication phase using the more attenuated smallpox vaccine strains by a further passage in cell culture or animals (LC16 and MVA-BN) [55]. In the year 2019, MVA-BN (JYNNEOS) was approved for the prevention of smallpox and monkeypox by the US FDA followed by national regulatory authorities such as US CDC and the European Medicines Agency (EMA) [52, 54-55]. However, due to the limited supply of

vaccine JYNNEOS, the USFDA issued an Emergency Use Authorization (EUA) on August 9, 2022, to administer the vaccine by intradermal injection for individuals ≥ 18 years to those at high risk for monkeypox infection [60].

In collaboration with local public health authorities, the Advisory Committee on Immunization Practices (ACIP) recommends the use of either the ACAM 2000 or MVA vaccine for specific health professionals at increased risk for occupational exposure to MPXV, including laboratory personnel conducting screening tests for Orth poxviruses [32]. For certain populations, such as toddlers, women who are pregnant or nursing, or those who have immune suppression, the monkeypox vaccine is typically not advised as a pre-exposure prophylaxis [32, 55]. After carefully weighing the risks and benefits, vaccination for monkeypox as post-exposure prophylaxis may be recommended for some demographic groups, such as those who are pregnant, have young children or have immune suppression, such as those who have HIV [32,55]. Individuals with a greater or intermediate risk of MPX contact and/or eligible for post-exposure prophylaxis should be vaccinated within four days of exposure [32,55]. According to the CDC guidelines, a high-risk exposure is considered as either "unprotected contact between a person's skin or mucous membranes and the skin, lesions, or bodily fluids from a person with monkeypox (sexual contact, inadvertent splashes of patient saliva to the eyes or oral cavity of a person, ungloved contact with the patient) or contaminated materials(clothing)" or "being inside the patient's room or within six feet of a patient during any procedures that may create aerosols from oral secretions, skin lesions, or resuspension of dried exudates without wearing an N95 or equivalent respirator and eye protection". Intermediate risk exposure considered as either "being within six feet for three hours or more of an unmasked person with monkeypox without wearing, at a minimum, a surgical mask" or "engaging in an activity that results in contact between sleeves and other parts of an individual's clothing and the patient's skin lesions or bodily fluids or their soiled linens or dressings (turning, bathing, or assisting with transfer) while wearing gloves but not wearing a gown" [32]. People who have been exposed to the MPXV and haven't had the smallpox vaccine in the past three years should think about receiving the vaccine [32]. ACAM2000 may be administered via a procedure called scarification for the indicated. Although vaccination can be considered for exposures lasting up to 14 days if administered between days 4 and 14, it is believed to lessen disease symptoms but not to prevent them. ACAM2000 is administered 4 weeks following the second dose of MVA-BN, at which point a person is deemed fully immunized[32]. Nevertheless, even after receiving the vaccine, individuals should keep taking precautions to prevent disease by preventing close, skin-to-skin contact, particularly intimate contact, with a person who has monkeypox [32,55].

Discussion & Conclusions

14

The most recent pandemic, COVID-19, reminds the need to constantly be prepared for new virus outbreaks. Viruses that haven't been observed in a while resurface. Currently, the monkeypox outbreak is a new viral infection threatening all healthcare authorities in the world because of the increasing number of cases in nonendemic regions of the world. However, despite the possibility of a new pandemic at any moment, new antiviral drugs and vaccines should be there to control the virus's severity and mortality. Because of variability in clinical features of the monkeypox outbreak 2022, such as lesions in the anogenital region and the mouth, hands and palms before (or without) other prodrome

symptoms, rectal pain and penile oedema, myalgia, lethargy, sore throat and asymptomatic cases as well. These novel clinical presentations

should be included in public health messaging to aid early diagnosis and reduce onward transmission. Hence, due to the increased rate of

hospitalization including intensive care unit admission and slowly rising fatality rate, clinicians must be vigilant to test and trace those patients

who present with these atypical symptoms and asymptomatic high-risk category population, predominantly heterosexuals and or men who have

sex with men.

Acknowledgement: None.

Funding: None.

Data Availability: The data used in this systematic review is available from the corresponding author with a reasonable request.

Conflict of interests: None.

Author Contributions: All authors contributed to the literature search, data extraction and draft of the manuscript. All authors reviewed and

approved the final version of the manuscript.

References:

- Multicountry monkeypox outbreak:situation update.Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON396.Accessed on: 28 July 2022.
- 2. 2022 Monkeypox Outbreak Global Map. Available from: https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html.Accessed on: 31 July 2022.
- 3. Nalca A, Rimoin AW, Bavari S, Whitehouse CA. Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis 2005. 41(12):1765–1771.
- 4. Jezek Z, Szczeniowski M, Paluku KM, Mutombo M. Human monkeypox: clinical features of 282 patients. J Infect Dis. 1987 Aug;156(2):293-8. doi: 10.1093/infdis/156.2.293.
- 5. Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, Steffen R. The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS Negl Trop Dis. 2022;16(2):e0010141. doi: 10.1371/journal.pntd.0010141.
- 6. Mungmunpuntipantip R, Wiwanitkit V. Dysphagia and Monkeypox: A Consideration. Dysphagia. 2022 Jun 20. doi: 10.1007/s00455-022-10481-x. Epub ahead of print. PMID: 35723740.
- 7. United States Centers for Disease Control and Prevention. Monkeypox: transmission. htt ps://www.cdc.gov/poxvirus/monkeypox/transmission.html (Accessed on July 03, 2022).
- 8. Semba RD. The ocular complications of smallpox and smallpox immunization. Arch Ophthalmol 2003; 121:715.
- 9. Reynolds MG, Yorita KL, Kuehnert MJ, Davidson WB, Huhn GD, Holman RC, Damon IK (2006) Clinical manifestations of human monkeypox influenced by route of infection. J Infect Dis 194 (6):773–780.
- 10. United States Centers for Disease Control and Prevention. CDC and health partners resp onding to monkeypox case in the U.S. https://www.cdc.gov/media/releases/2022/s0518-.
- 11. United States Centers for Disease Control and Prevention. CDC and Texas Confirm Monk eypox In U.S. Traveler https://www.cdc.gov/media/releases/2021/s0716-confirm-monkey.pox.html (Accessed on July 21, 2021)

- 12. Nolen LD, Osadebe L, Katomba J, Likofata J, Mukadi D, Monroe B, Reynolds MG .Extended human-to-human transmission during a monkeypox outbreak in the Democratic Republic of the Congo. Emerg Infect Dis2016. 22(6):1014–21. https://doi.org/10.3201/eid2206. 150579.
- 13. World Health Organization. Monkeypox fact sheet. https://www.who.int/news-room/factsheets/detail/monkeypox (Accessed on May 23, 2022).
- 14. Mbala PK, Huggins JW, Riu-Rovira T, Ahuka SM, Mulembakani P, Rimoin AW, Muyembe JT. Maternal and fetal outcomes among pregnant women with human monkeypox infection in the Democratic Republic of Congo. J Infect Dis 2017.216(7):824–8.
- 15. Sklenovská, N. Monkeypox Virus. In: Malik, Y.S., Singh, R.K., Dhama, K. (eds) Animal-Origin Viral Zoonoses. Livestock Diseases and Management 2020. Springer.https://doi.org/10.1007/978-981-15-2651-0_2.
- 16. WHO Director-General declares the ongoing monkeypox outbreak a Public Health Emergency of International Concern. Available at:https://www.who.int/europe/news/item/23-07-2022-who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public-health-event-of-international-concern. Accessed on: 28 July 2022.
- 17. Huhn GD, Bauer AM, Yorita K, Graham MB, Sejvar J, Likos A, Damon IK, Reynolds MG, Kuehnert MJ. Clinical characteristics of human monkeypox, and risk factors for severe disease. Clin Infect Dis. 2005 Dec 15;41(12):1742-51. doi: 10.1086/498115.
- 18. Minhaj FS, Ogale YP, Whitehill F, et al. Monkeypox Outbreak Nine States, May 2022. MMWR Morb Mortal Wkly Rep 2022; 71:764.
- 19. Hammerschlag Y, MacLeod G, Papadakis G, Adan Sanchez A, Druce J, Taiaroa G, et al. Monkeypox infection presenting as genital rash, Australia, May 2022. Euro Surveill. 2022 Jun;27(22):2200411. doi: 10.2807/1560-7917.ES.2022.27.22.2200411.
- 20. Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al; SHARE-net Clinical Group. Monkeypox Virus Infection in Humans across 16 Countries April-June 2022. N Engl J Med. 2022 Jul 21. doi: 10.1056/NEJMoa2207323.
- 21. Tarín-Vicente, E J, Agud-Dios, M, Alemany, A, Ubals, M, Suñer, C, Antón, A, et al. Clinical Presentation and Virological Assessment of Confirmed Human Monkeypox Virus Cases in Spain: A Prospective Cohort Study. Available at SSRN: https://ssrn.com/abstract=4162718 or http://dx.doi.org/10.2139/ssrn.4162718.
- 22. Orviz E, Negredo A, Ayerdi O, Vázquez A, Muñoz-Gomez A, Monzón S, et al. Monkeypox outbreak in Madrid (Spain): Clinical and virological aspects. J Infect. 2022 Jul 10:S0163-4453(22)00415-7. doi: 10.1016/j.jinf.2022.07.005.

- 23. Perez Duque M, Ribeiro S, Martins JV, Casaca P, Leite PP, Tavares M, et al. Ongoing monkeypox virus outbreak, Portugal, 29 April to 23 May 2022. Euro Surveill. 2022 Jun;27(22):2200424. doi: 10.2807/1560-7917.ES.2022.27.22.2200424.
- 24. Iñigo Martínez J, Gil Montalbán E, Jiménez Bueno S, Martín Martínez F, Nieto Juliá A, Sánchez Díaz J, et al. Monkeypox outbreak predominantly affecting men who have sex with men, Madrid, Spain, 26 April to 16 June 2022. Euro Surveill. 2022 ;27:2200471. doi: 10.2807/1560-7917.ES.2022.27.27.2200471.
- 25. Miura F, van Ewijk CE, Backer JA, Xiridou M, Franz E, Op de Coul E, et al. Estimated incubation period for monkeypox cases confirmed in the Netherlands, May 2022. Euro Surveill. 2022 Jun;27(24):2200448. doi: 10.2807/1560-7917.ES.2022.27.24.2200448.
- 26. Peiró-Mestres A, Fuertes I, Camprubí-Ferrer D, Marcos MÁ, Vilella A, Navarro M, et al; Hospital Clinic de Barcelona Monkeypox Study Group. Frequent detection of monkeypox virus DNA in saliva, semen, and other clinical samples from 12 patients, Barcelona, Spain, May to June 2022. Euro Surveill. 2022 Jul;27(28). doi: 10.2807/1560-7917.ES.2022.27.28.2200503.
- 27. Girometti N, Byrne R, Bracchi M, Heskin J, McOwan A, Tittle V, et al. Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis. Lancet Infect Dis. 2022 Jul 1:S1473-3099(22)00411-X. doi: 10.1016/S1473-3099(22)00411-X.
- 28. Patel A, Bilinska J, Tam JCH, Da Silva Fontoura D, Mason CY, Daunt A, et al. Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series. BMJ. 2022 Jul 28;378:e072410. doi: 10.1136/bmj-2022-072410.
- 29. Antinori A, Mazzotta V, Vita S, et al. Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022. Euro Surveill 2022.
- 30. Reynolds MG, McCollum AM, Nguete B, Shongo Lushima R, Petersen BW. Improving the Care and Treatment of Monkeypox Patients in Low-Resource Settings: Applying Evidence from Contemporary Biomedical and Smallpox Biodefense Research. Viruses. 2017 Dec 12;9(12):380. doi: 10.3390/v9120380.
- 31. Semba RD. The ocular complications of smallpox and smallpox immunization. Arch Ophthalmol. 2003 May;121(5):715-9. doi: 10.1001/archopht.121.5.715.

- 32. United States Centers for Diseae Control and Prevention. Interim clinical guidance for the treatment of monkeypox. https://www.cdc.gov/poxvirus/monkeypox/clinicians/treatment.html (Accessed on July 12, 2022).
- 33. World Health Organization. Clinical management and infection prevention and control for monkeypox. Interm rapid response guidance. 10 June 2022. https://www.who.int/public ations/i/item/WHO-MPX-Clinical-and-IPC-2022.1 (Accessed on July 13, 2022).
- 34. Altmann S, Brandt CR, Murphy CJ, Patnaikuni R, Takla T, Toomey M, Nesbit B, McIntyre K, Covert J, Dubielzig R, Leatherberry G, Adkins E, Kodihalli S. Evaluation of therapeutic interventions for vaccinia virus keratitis. J Infect Dis. 2011 Mar 1;203(5):683-90. doi: 10.1093/infdis/jiq103. Epub 2011 Jan 28.
- 35. Abdelaal A, Serhan HA, Mahmoud MA, Rodriguez-Morales AJ, Sah R. Ophthalmic manifestations of monkeypox virus. Eye (Lond). 2022 Jul 27. doi: 10.1038/s41433-022-02195-z.
- 36. Fine PE, Jezek Z, Grab B, Dixon H. The transmission potential of monkeypox virus in human populations. Int J Epidemiol. 1988 Sep;17(3):643-50. doi: 10.1093/ije/17.3.643.
- 37. WHO. Vaccines and immunization for monkeypox. file:///C:/Users/Admin/Downloads/WHO-MPX-Immunization-2022.1-eng%20(1).pdf.
- 38. FDA approves the first drug with an indication for treatment of smallpox. https://www.fd a.gov/NewsEvents/Newsroom/PressAnnouncements/ucm613496.html(Accessed on July 18, 2018).
- 39. Jordan R, Goff A, Frimm A, Corrado ML, Hensley LE, Byrd CM, et al. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother. 2009 May;53(5):1817-22.
- 40. Adler H, Gould S, Hine P, et al.. Clinical features and management of human monkeypox: Lancet Infect Dis 2022. 10.1016/S1473-3099(22)00228-6 (Accessed on May 27, 2022).
- 41. Merchlinsky M, Albright A, Olson V, Schiltz H, Merkeley T, Hughes C, Petersen B, Challberg M. The development and approval of tecoviromat (TPOXX®), the first antiviral against smallpox. Antiviral Res. 2019:168-174. doi: 10.1016/j.antiviral.2019.06.005.
- 42. Rao AK, Schulte J, Chen TH, et al. Monkeypox in a Traveler Returning from Nigeria Dallas, Texas, July 2021. MMWR Morb Mortal Wkly Rep 2022; 71:509.

- 43. Baker RO, Bray M, Huggins JW. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res 2003; 57:13
- 44. Andrei G, Snoeck R. Cidofovir Activity against Poxvirus Infections. Viruses. 2010;2:2803-30. doi: 10.3390/v2122803.
- 45. Hopkins RJ, Lane JM. Clinical efficacy of intramuscular vaccinia immune globulin: a literature review. Clin Infect Dis. 2004 Sep 15;39:819-26. doi: 10.1086/422999.
- 46. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis. 2003;37:251–271.
- 47. Hutson CL, Kondas AV, Mauldin MR, Doty JB, Grossi IM, Morgan CN, et al. Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model. mSphere. 2021;:e00927-20. doi: 10.1128/mSphere.00927-20. Erratum in: mSphere. 2021 Feb 17;6(1):
- 48. Pittman, P.R., et al., Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox. N Engl J Med, 2019. 381: p. 1897-1908. 22.
- 49. Khalil A, Samara A, O'Brien P, Morris E, Draycott T, Lees C, Ladhani S. Monkeypox vaccines in pregnancy: lessons must be learned from COVID-19. Lancet Glob Health. 2022;S2214-109X(22)00284-4. doi: 10.1016/S2214-109X(22)00284-4.
- 50. ACAM2000, (Smallpox (Vaccinia) Vaccine, Live) Lyophilized preparation for percutaneous scarification.available from:https://www.fda.gov/media/75792/download.
- 51. Daniel R.Lucey.The two-dose monkeypox vaccine, JYNNEOS, licensed by FDA in 2019. Accessed on: https://www.idsociety.org/science-speaks-blog/2022/the-two-dose-monkeypox-vaccine-jynneos-licensed-by-fda-in 2019/#/+/0/publishedDate_na_dt/desc/.
- 52. Eto A, Yamamoto N, Kanatani Y. Effect of Serial Passage on the Pathogenicity and Immunogenicity of Vaccinia Virus LC16m8 Strain. Biology (Basel). 2021 Nov 9;10(11):1158. doi: 10.3390/biology10111158.
- 53. Lansiaux, E., et al., The Virology of Human Monkeypox Virus (hMPXV): A Brief Overview.
- 54. Monkeypox vaccine from Bavarian Nordic wins EU approval. Available from:https://www.reuters.com/business/healthcare-pharmaceuticals/bavarian-nordic-monkeypox-vaccine-wins-eu-approval-2022-07-25/.
- 55. WHO. Vaccines and immunisation for monkeypox: interim guidance, June 14 2022. 2022, World Health Organization. Available on: file:///C:/Users/Admin/Downloads/WHO-MPX-Immunization-2022.1-eng.pdf. accessed on 28 July 2022.

- 56. Joint ECDC-WHO Regional Office for Europe Monkeypox Surveillance Bulletin. Available at: https://monkeypoxreport.ecdc.europa.eu/. (Accessed on August 05, 2022).
- 57. Chenchula S, Karunakaran P, Sharma S, Chavan M. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review. J Med Virol. 2022;94:2969-76. doi: 10.1002/jmv.27697.
- 58. Santenna C, Vidyasagar K, Amarneni KC, Ghanta SN, Sadasivam B, Pathan S, et al. The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis. Ther Adv Drug Saf. 2021 Sep 24;12:20420986211042517. doi: 10.1177/20420986211042517.
- 59. Desai AN, Thompson GR 3rd, Neumeister SM, Arutyunova AM, Trigg K, Cohen SH. Compassionate Use of Tecovirimat for the Treatment of Monkeypox Infection. JAMA. 2022 Aug 22. doi: 10.1001/jama.2022.15336.
- 60. Monkeypox Update: FDA Authorizes Emergency Use of JYNNEOS Vaccine to Increase Vaccine Supply. Available at: https://www.fda.gov/media/160774/download#:~:text=Information%20Regarding%20Available%20Alternatives%20for,for%20smallpox%20or%20monkeypox%20infection.
- 61. De Baetselier, I., Van Dijck, C., Kenyon, Coppens J, Michiels J, de Block T C. *et al.* Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium. *Nat Med* (2022). https://doi.org/10.1038/s41591-022-02004-w.
- 62. Ferré VM, Bachelard A, Zaidi M, Armand-Lefevre L, Descamps D, Charpentier C, et al. Detection of Monkeypox Virus in Anorectal Swabs From Asymptomatic Men Who Have Sex With Men in a Sexually Transmitted Infection Screening Program in Paris, France. Ann Intern Med. 2022. doi: 10.7326/M22-2183.
- 63. Tarín-Vicente EJ, Alemany A, Agud-Dios M, Ubals M, Suñer C, Antón A, et al. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. Lancet. 2022 Aug 27;400(10353):661-669. doi: 10.1016/S0140-6736(22)01436-2.

64. Girometti N, Byrne R, Bracchi M, Heskin J, McOwan A, Tittle V, et al. Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis. Lancet Infect Dis. 2022:1321-8. doi: 10.1016/S1473-3099(22)00411-X.

5.N	Number of patients	Median Age	Country	Patient characteristics & Incubation period	Previous smallpox or other Vaccinatio n status	Specimen samples for diagnosis	Clinical symptoms & Number of Hospitalizations	Treatment	Mortalit y	Reference
2	181	37	43 sites in 16 countries.	 Heterosexuals:2%: HIV: 41% (on antiretroviral therapy.) STDs: 29%. The median incubation period: 7 days (3-20). Male: 96·7%. Gay or bisexual men: 166 	17.7%	Swab specimens of the skin or genital lesion with throat or nasopharyngeal and blood. RT-PCR Swab specimens of the skin or genital lesions, with throat or	Rash: 95 %(< 10 lesions: 64%) • Anogenital lesions:73% • Mucosal lesions: 41% • Fever:62% • Lethargy:41% • Myalgia: 31% • Headache:27% • Lymphadenopathy:56% • Number of Hospitalizations: 70(13%) • Fever: 72·4%. • Influenza-like illness: 81.2%. • Sore throat: 36.5%.	Tecovirimat. Topical cidofovir And symptomatic treatment. Supportive and Symptomatic treatment.	0	By al. [20] All rights reserved. No rejuse. Tarin- raise. Tet al. [20] Tet al. [20]
				 (91·7%). HIV: 73% (All are receiving antiretroviral therapy.) The median incubation period: 7 Days (5-10). 		nasopharyngeal RT-PCR	 Headache: 53% Lymphadenopathy:84.5%. Lesions in the urogenital region: 77.9%. Lesions in the oral and perioral region: 43.1%. Proctitis:24.9% Tonsillitis:10.5% Bacterial skin abscess:3.3%. Number of Hospitalization: 178 (98.3%) 			allowed
3	48	35	Spain	Male:100% Gay or bisexual men: 87.5%	• NA	Swabs of lesion surfaces, exudate from lesions in the palms, genital area, and/or oral mucosa. RT-PCR	 Vesicular-umbilical and pseudopustular skin lesions: 93.8%. Asthenia:66.6% Fever:52.1% Number of Hospitalization: 35 (72.91%)	Supportive and Symptomatic treatment.	0	without permission. Orviz E al.[22] Perez
1	27	33 years	Portugal	• Male: 100%.	• 1%	Swabs of lesion	• Exanthema:14(51.8%)	Supportive and	0	Perez 🖹

5	508	35 years	Spain	• HIV: 14 Male:99% Gay or bisexual Men: 93%. HIV:44.3%	• 11%	•	Swabs of lesion surfaces, exudate and/or crusts from lesions in the palms, genital area, and/or oral mucosa. RT-PCR and genomic sequencing	Inguinal lymphadenop athy:14(51.8%) Fever:13(48.14%) Asthenia:7(25.9%) Genital ulcers:6(22.2%) Genital vesicles:6(22.2%) Anal ulcers:5(18.51%) Myalgia:5(18.51%) Anal Vesicles:4(14.81) Cervical lymphadenopathy:4(14.81%) Axillary lymphadenopathy:2 (7.4%) Number of Hospitalization: 3 (11.11%) Exanthema: 14(2.75%) Inguinal lymphadenopathy: 14(2.75%) Fever: 13 (2.55%) Asthenia: 7 (1.3%) Headache: 7(1.3%) Genital ulcers: 6 (1.1%) Genital vesicles: 6 (1.1%0 Anal ulcers: 5 (0.9%) Myalgia: 5 (0.9%) Anal Vesicles: 4 (0.78%) Cervical lymphadenopathy: 4(0.78%) Axillary lymphadenopathy: 4(0.78%) Cervical lymphadenopathy: 4(0.78%) Axillary lymphadenopathy: 4(0.78%)	Supportive Symptomatic treatment.	and	0	Duque et al [23] All rights resented in the mission without permission. Iñigo Martined Miurasion. Miurasion. Miurasion.
j	18	23-64 years	Netherlands	Male: 100%. Median incubation period: 8.5 days.	• NA	•	NA	 Number of Hospitalization: 19(3.7%) Fever, Headache, myalgia, and general malaise. Skin lesions in Genital and Anal area, lymphadenopathy. Number of Hospitalization:100% 	Supportive Symptomatic treatment.	and	0	Miuragi al.[25].

								N N
7 12		38.5 years	Barcelona	Male:100%HIV: 4.STDs:3	7(58.3%)	•	Swab specimens of Saliva, Rectal swab, nasopharyngeal swab, semen, urine and faeces. RT-PCR	An unspecific systemic syndrome consists of Fever, Asthenia, Headache, myalgia, and general malaise. Skin lesions in Arm, perianal area and trunk, Genital area, Chest and legs, Wrist, pectoral, fingers, hand, Ulcerated ventral tongue, Genital ulcers, Genital vesicles, Anal ulcers, Odynophagia Anal Vesicles, Cervical lymphadenopathy, Axillary lymphadenopathy Number of Hospitalization: 19 (3.7%) Fatigue/Lethargy: 67% Supportive and O Giron of Hospitalization: 19 (3.7%) Supportive and O Giron of Hospitalization: 19 (3.7%) Supportive and O Giron of Hospitalization: 19 (3.7%) No prodromal symptoms: 18%
3 54		41 years	London, UK	 Male:100% HIV: 24% STDs: 1 in 4 patients. 	• NA	•	Swab specimens of lesion surfaces. RT-PCR	• Fatigue/Lethargy: 67% • Fever: 57% • No prodromal symptoms: 18% • Skin lesions: 100% • Anogenital lesions: 94% • Oropharyngeal lesions: 7% • Lymphadenopathy: 55% Number of Hospitalization: 9%
) 197	7		South London, UK	 Male: 100% Gay/bisexual: 99.5% HIV: 35.9% (n=195, n=?2) STDs: 31.5% 	• NA		Swab specimens of lesion surfaces. RT-PCR	Skin lesions: 100% Anogenital lesions: 94% Dropharyngeal lesions: 7% Lymphadenopathy: 55% Number of Hospitalization: 9% Fever: 61.9% Lymphadenopathy: 57.9% Lymphadenopathy: 57.9% Lymphadenopathy: 57.9% Myalgi a: 31.5% Mucocutaneous lesions on Genital lesions: 56.3% Perianal lesions: 41.6% Perianal lesions: 41.6% Mucocutaneous manifestations without prodromal systemic features: 13.7% Oropharyngeal lesions: 13.7% Tonsillar involvement: 4.6% Perianal Abscess: 1.5%. Sore throat: 16.8% Necrotizing Supportive and Symptomatic treatment. Supportive and Symptomatic treatment. Hospitalized for the treatment of Severe rectal pain requiring: 0.5%. Proctitis: 2.5%. Necrotizing Secondary bacterial infection: 0.5% Sore throat: 16.8%

								· ·	Rectal pain:36% Penile oedema:15.7% Rectal pain with rectal perforation: 0.5%. mber of Hospitalization: 10.2%			
4	30 years	Italy	 Male: 100% Gay/bisexual: 100% STDs: 100%. HIV:50% 	•	NA	•	Swab specimens of lesion surfaces. RT-PCR	•	Fever: 50% Myalgi a: 25% No systemic symptoms: 25% Lesions in Genital, pubic area, thorax, Anal, back, legs, foot sole, calf area, head, arms and hand. Number of Hospitalizations: 100%	No specific antiviral therapy. Anti-inflammatory and antihistaminic drugs.	0	Anting A et al
7	30 years	London Liverpool	 Male: 58% Gay/bisexual: 100% STDs: 0. HIV: 0 	•	NA	•		•	Fever:58% Lymphadynopathy:72% Lesions on Face, scalp, trunk, limbs, palms, glans penis, and scrotum Number of Hospitalization: 100%	3 patients were treated with antiviral Brincidofovir 200 mg: 6-7 days (ADR: increased liver transaminases) One patient has received Tecovirimat 600 mg twice daily for 2 weeks orally: 5 days(ADRs: None).	0	Adler al[40] https://nkeyp.port.ec.europ[94]
15524	31-40 years	European region	 Male: 58% Gay/bisexual: 99.1% STDs: 0. HIV:36% Healthcare workers:2.2% 	•	NA	•	Swab specimens of the throat or oropharyngeal, lesion crust, Saliva, Rectal swab, nasopharyngeal swab, semen, urine and faeces, and blood.	•	Rash:94.8% Anogenital lesions:44.8% Oral lesions:11.5% Skin & mucosal lesions:46.7% Lymphadynopathy:7.6% Sorethroat:8.9% Systemic symptoms (fever, myalgia, fatigue, chils, hedeach): 65%.	Total no. of hospitalized patients required clinical care: 150.	2	https:// nkeyp port.e- europ .[94]

				• RT-PCR	• Total no. of patients hospitalized: 399((2.5%).		
25	40.7 years (26-76) California	Male:100% HIV: 1(1%).	Smallpox: 1 JYNNEOS: 4 (1 dose after symptom onset)	Anorectal and/or oropharyngeal swabs. RT-PCR	 Systemic symptoms, lesions, or both were present for a mean of 12 days (range:6-24). Fever: 19 (76%) Headache:8 (32%), Fatigue:7 (28%) Sore throat:5 (20%) Chills; 5 (20%) Backache:3 (12%) Myalgia: 2 (8%) Nausea:1 (4%) Diarrhea:1 (4%). Genital and/or perianal lesions: 23 [92%]) Fewer than 10 lesions over entire body: 13 (52%) Pain associated with lesions: All patients. Total no. of hospitalizations: 25(100%) 	Oral Tecovirimat 14 days: 24 patients 21 days: 1 patient • Complete resolution of lesions on day 7 of therapy: 10(40%). • Complete Resolution of lesions and pain by day 21: 23 (92%). • Well tolerated. • The most common adverse events on day 7: • Fatigue:7(28%). Headache: 5(20%) • Nausea:4(16%) • Itching:2(8%) • Diarrhea: 2 (8%).	O Desai et al [9]

													0)
14	224	30-50 years	Belgium	•	Male:100% HIV & STDs:4	NA	•	Anorectal and/or oropharyngeal swabs. RT-PCR positive: 4(1.8%)	• • Tota	Painful vesicular perianal rash: 1 Asymptomatic: 3 Il no. of hospitalizations: 0	NA	0	De not gentified by
15	213	38 years	Paris, France	•	Male:100% HIV: 52%	NA	•	Anorectal swabs RTPCR positive: 13(6.5%)	• Tota	Asymptomatic: 13(6.5%). al no. of hospitalizations: 0	NA	0	Ferre Voor et al [100]
16	181	37·0 years (IQR 31·0– 42·0)	Spain	•	Gay or Bisexual Men or MSM: 166 (92%). Heterosexual men or women: 15 (8%). HIV: 72 (40%) STDs: 31 (17%). The median incubation period: 7 days (IQR 5·0–10·0).	Smallpox: 32 (18%).	•	Swabs from skin lesions and throat	•	Systemic symptoms before the rash:67 [62%] Lesions in the anogenital region: 141 (78%) Lesions in the oral and perioral region:78 (43%) Complications requiring treatment: 70 (39%) proctitis: 45 (25%). Tonsillitis:19 (10%) Penile oedema: 15 (8%). Abscess:6(3%) Exanthema: 8(4%)	The median time from onset of lesions to formation of a dry crust : 10 days (IQR 7–13)	0	iew) is the author/funder, who has granted m All rights reserved. No reuse allowed with
l7	54	41 years (IQR 34- 45).	London, UK	•	Gay or Bisexual Men or MSM: 166(92%). HIV: 13 (24%) STDs;1:4	NA	•	Anorectal and/or oropharyngeal swabs. RT-PCR	· · · · · · Tota	Fatigue: 36(67%) Fever: 31 (57%) No prodromal symptoms: 10(18%). Anogenital lesions: 51 (94%) Skin lesions: 37 (89%) Oropharyngeal lesions: 4(7%). Lymphadenopathy: 30 (55%).	Total hospitalization: 5(9%) due to pain or localised bacterial cellulitis requiring antibiotic intervention or analgesicies.	0	who has granted medRiv a license to display the preuse allowed without permission. G N all 102

Table 1. Clinical studies of 2022 Monkeypox outbreak.

MPX:Monkeypox; HIV: Human Immuno Deficiency; STD: Sexually Transmitted disease: RTPCR: reverse transcriptase polymerase chain reaction. MSM: Men who have sex with men; NA: Not Available.

Figure 1: PRISMA Flow Diagram for the study selection.

Identification of studies via in Pub Med, Google Scholar and Cochrane Library and Grey literature by Using Following MESH or Key words

